Overview

A Phase I Clinical Study of JS004 Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors

Status:
Not yet recruiting

Trial end date:
2025-07-31

Target enrollment:

Participant gender:

Summary

This is an open-label phase I study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of JS004 injection combined with Toripalimab Injection in patients with advanced solid tumors who have failed standard therapy.

Phase:

Phase 1

Details

Lead Sponsor:

Shanghai Junshi Bioscience Co., Ltd.

Collaborator:

Sponsor GmbH